JP2018509457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509457A5 JP2018509457A5 JP2017550541A JP2017550541A JP2018509457A5 JP 2018509457 A5 JP2018509457 A5 JP 2018509457A5 JP 2017550541 A JP2017550541 A JP 2017550541A JP 2017550541 A JP2017550541 A JP 2017550541A JP 2018509457 A5 JP2018509457 A5 JP 2018509457A5
- Authority
- JP
- Japan
- Prior art keywords
- theta
- solvate
- peaks
- crystalline form
- thermogram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021187233A JP2022033783A (ja) | 2015-03-27 | 2021-11-17 | ブルトン型チロシンキナーゼ阻害剤の溶媒和形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139594P | 2015-03-27 | 2015-03-27 | |
| US62/139,594 | 2015-03-27 | ||
| PCT/US2016/024305 WO2016160598A1 (en) | 2015-03-27 | 2016-03-25 | Solvated forms of a bruton's tyrosine kinase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021187233A Division JP2022033783A (ja) | 2015-03-27 | 2021-11-17 | ブルトン型チロシンキナーゼ阻害剤の溶媒和形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018509457A JP2018509457A (ja) | 2018-04-05 |
| JP2018509457A5 true JP2018509457A5 (enExample) | 2019-05-09 |
Family
ID=57006292
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550541A Pending JP2018509457A (ja) | 2015-03-27 | 2016-03-25 | ブルトン型チロシンキナーゼ阻害剤の溶媒和形態 |
| JP2021187233A Pending JP2022033783A (ja) | 2015-03-27 | 2021-11-17 | ブルトン型チロシンキナーゼ阻害剤の溶媒和形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021187233A Pending JP2022033783A (ja) | 2015-03-27 | 2021-11-17 | ブルトン型チロシンキナーゼ阻害剤の溶媒和形態 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20180072738A1 (enExample) |
| EP (1) | EP3273961A4 (enExample) |
| JP (2) | JP2018509457A (enExample) |
| CN (1) | CN107530346A (enExample) |
| AU (1) | AU2016243116A1 (enExample) |
| BR (1) | BR112017020744A2 (enExample) |
| CA (1) | CA2981048A1 (enExample) |
| HK (2) | HK1248147A1 (enExample) |
| MA (1) | MA41827A (enExample) |
| MX (1) | MX2017012430A (enExample) |
| WO (1) | WO2016160598A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013184572A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| EP3337485B1 (en) * | 2015-08-19 | 2021-03-17 | Sun Pharmaceutical Industries Ltd | Crystalline forms of ibrutinib |
| CZ2016276A3 (cs) * | 2016-05-11 | 2017-11-22 | Zentiva, K.S. | Pevné formy volné báze ibrutinibu |
| US10183024B2 (en) | 2016-12-02 | 2019-01-22 | Apotex Inc. | Crystalline forms of ibrutinib |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| EP3575300A1 (en) | 2018-05-31 | 2019-12-04 | Apotex Inc. | Novel crystalline forms of ibrutinib |
| EP3669867A1 (en) | 2018-12-21 | 2020-06-24 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| US10688050B1 (en) | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| CN114829370B (zh) * | 2019-09-18 | 2025-10-28 | 普莱鲁德疗法有限公司 | 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 |
| WO2022083733A1 (zh) * | 2020-10-23 | 2022-04-28 | 上海润石医药科技有限公司 | 固体形式的布鲁顿酪氨酸激酶抑制剂化合物及其用途 |
| WO2023242384A1 (en) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Crystalline form of ibrutinib |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| DE3303707A1 (de) * | 1983-02-04 | 1984-08-09 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| AU1537292A (en) | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
| AU661080B2 (en) | 1991-11-22 | 1995-07-13 | Warner Chilcott Company, Llc | Risedronate delayed-release compositions |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| KR100291362B1 (ko) | 1992-10-16 | 2001-09-17 | 니뽄 신야쿠 가부시키가이샤 | 왁스매트릭스의제법 |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| EP0827402A2 (en) | 1995-05-17 | 1998-03-11 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
| CO5210907A1 (es) * | 1999-05-12 | 2002-10-30 | Novartis Ag | Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| GB0108903D0 (en) * | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| EP1664762A4 (en) | 2003-09-03 | 2008-08-13 | Us Gov Health & Human Serv | METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA |
| PL2526933T3 (pl) | 2006-09-22 | 2015-08-31 | Pharmacyclics Llc | Inhibitory kinazy tyrozynowej Brutona |
| SG10201508035TA (en) * | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
| US8541391B2 (en) * | 2010-10-28 | 2013-09-24 | Viropharma Incorporated | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole |
| US8501484B2 (en) * | 2011-03-14 | 2013-08-06 | Los Alamos National Security, Llc | Preparation of cerium halide solvate complexes |
| WO2013184572A1 (en) * | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| AU2014251028A1 (en) | 2013-04-08 | 2015-11-05 | Janssen Pharmaceutica Nv | Ibrutinib combination therapy |
| CN106008521A (zh) * | 2014-01-29 | 2016-10-12 | 苏州晶云药物科技有限公司 | 依鲁替尼的新晶型及其制备方法 |
-
2016
- 2016-03-24 MA MA041827A patent/MA41827A/fr unknown
- 2016-03-25 HK HK18107889.9A patent/HK1248147A1/zh unknown
- 2016-03-25 MX MX2017012430A patent/MX2017012430A/es unknown
- 2016-03-25 CA CA2981048A patent/CA2981048A1/en not_active Abandoned
- 2016-03-25 WO PCT/US2016/024305 patent/WO2016160598A1/en not_active Ceased
- 2016-03-25 JP JP2017550541A patent/JP2018509457A/ja active Pending
- 2016-03-25 HK HK18109251.5A patent/HK1249737A1/zh unknown
- 2016-03-25 BR BR112017020744A patent/BR112017020744A2/pt not_active Application Discontinuation
- 2016-03-25 EP EP16773859.0A patent/EP3273961A4/en not_active Withdrawn
- 2016-03-25 AU AU2016243116A patent/AU2016243116A1/en not_active Abandoned
- 2016-03-25 US US15/561,615 patent/US20180072738A1/en not_active Abandoned
- 2016-03-25 CN CN201680026436.5A patent/CN107530346A/zh active Pending
-
2018
- 2018-12-18 US US16/224,565 patent/US20190367519A1/en not_active Abandoned
-
2019
- 2019-11-27 US US16/697,865 patent/US20200347063A1/en not_active Abandoned
-
2021
- 2021-05-12 US US17/318,148 patent/US20220106317A1/en not_active Abandoned
- 2021-11-17 JP JP2021187233A patent/JP2022033783A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509458A5 (enExample) | ||
| JP2012176975A5 (enExample) | ||
| JP2015010091A5 (enExample) | ||
| JP2016505010A5 (enExample) | ||
| JP2015518885A5 (enExample) | ||
| JP2018035160A5 (enExample) | ||
| JP2020512316A5 (enExample) | ||
| JP2017527578A5 (enExample) | ||
| JP2007521340A5 (enExample) | ||
| FI2854859T3 (fi) | Brutonin tyrosiinikinaasin estäjän kiteisiä muotoja | |
| JP2015500331A5 (enExample) | ||
| JP2022507251A5 (enExample) | ||
| JP2019532919A5 (enExample) | ||
| CN116134028A (zh) | 一种具有降解btk激酶的化合物及其制备方法和药学上的应用 | |
| RS52663B2 (sr) | Nova kristalna forma tiotropijum bromida i proces njene pripreme | |
| JP2020536893A5 (enExample) | ||
| JP2015522037A5 (enExample) | ||
| JP2012211968A5 (enExample) | ||
| JP2020502224A5 (enExample) | ||
| JP2025511847A5 (enExample) | ||
| JP2013520488A5 (enExample) | ||
| TW201335161A (zh) | 二氫吡咯并［１，２－ｃ］咪唑基皮質醛酮素合成酶或芳族酶抑制劑之新穎型式及鹽 | |
| JP2015506987A5 (enExample) | ||
| JP2016512518A (ja) | ベムラフェニブ塩酸塩の固体形態 | |
| JP2013541589A5 (enExample) |